Research & Innovation
Publications

Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer.

#2005

#ANTI-CANCER DRUGS

PMU Authors
Roland Reitsamer, Florentia Peintinger, Wolfgang Hitzl

All Authors
Roland Reitsamer, Florentia Peintinger, Eva Prokop, Wolfgang Hitzl

Journal association
ANTI-CANCER DRUGS

Abstract

We are sorry. The full text is not available.

Keywords

TUMORS, WOMEN, CARCINOMA, SURGICAL ADJUVANT BREAST, PREOPERATIVE CHEMOTHERAPY, DOXORUBICIN, B-18

Latest Publication

#2025

#Abstract

Valentin Fischill-Neudeck, Antje van der Zee-Neuen, Margitta B. Beil-Hildebrand Strengthening Professional Health Literacy: A Theory-Based Approach to Empower Nursing Practice

#2025

#Original Article

Margaux Delporte, Johan Verbeeck, Isabella Brambilla, Georg Zimmermann, Geert Molenberghs, Rima Nabbout, Dravet syndrome, REGISTRY; RARE DISEASES; DRAVET SYNDROME; Natural history;

#2025

#Editorial

Eunkyeong Oh, Alberto Lucchini, Peter Nydahl Personalized approaches to ICU Distress

Back to Overview

Paracelsus Medical University (PMU) Research & Innovation Publications

Pathological complete response rates comparing 3...